Literature DB >> 28094015

A Nordic multicenter survey of long-term bowel function after transanal endorectal pull-through in 200 patients with rectosigmoid Hirschsprung disease.

Kristin Bjørnland1, Mikko P Pakarinen2, Pernilla Stenstrøm3, Kjetil J Stensrud4, Malla Neuvonen2, Anna L Granström5, Christina Graneli3, Are H Pripp6, Einar Arnbjörnsson3, Ragnhild Emblem4, Tomas Wester5, Risto J Rintala2.   

Abstract

OBJECTIVE: Transanal endorectal pull-through (ERPT) is the most popular technique to treat Hirschsprung disease (HD). Still, there is limited knowledge on long-term bowel function. This cross-sectional, multicenter study assessed long-term bowel function in a large HD population and examined predictors of poor outcome.
METHODS: Patients older than four years or their parents filled out a validated questionnaire on bowel function. Clinical details were recorded retrospectively from medical records.
RESULTS: 73/200 (37%) patients reported absolutely no impaired bowel function, meaning no constipation, fecal accidents, stoma, appendicostomy or need for enemas. Seven (4%) had a stoma, and 33 (17%) used antegrade or rectal colonic enemas. Most disarrangements of fecal control and constipation were significantly less common in older age group, but abnormal defecation frequency and social problems remained unchanged. Syndromic patients (n=31) experienced frequent fecal accidents (46%) more often than nonsyndromic (14%, P<0.001). Having a syndrome (adjusted OR 5.6, 95% CI 2.1-15, P=0.001) or a complete transanal ERPT (adjusted OR 2.4, 95% CI 1.1-5.7, P=0.038) was significantly associated with poor outcome defined as having a stoma, an appendicostomy, daily fecal accidents or need of regular rectal wash outs.
CONCLUSION: A significant number of HD patients experience bowel problems many years after definite surgery. Fecal control was significantly better in older than younger HD patients, but some continued to have considerable bowel problems also as adults. A total transanal ERPT was associated with poorer outcome. Long-term follow-up of HD patients is warranted. Prognosis Study: Level II.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Enterocolitis; Fecal incontinence; Hirschsprung; Long-term bowel function; Pull-through

Mesh:

Year:  2017        PMID: 28094015     DOI: 10.1016/j.jpedsurg.2017.01.001

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  15 in total

1.  Hirschsprung's disease in the laparoscopic transanal pull-through era: implications of age at surgery and technical aspects.

Authors:  Go Miyano; Masahiro Takeda; Hiroyuki Koga; Manabu Okawada; Nana Nakazawa-Tanaka; Junya Ishii; Takashi Doi; Geoffrey J Lane; Tadaharu Okazaki; Masahiko Urao; Atsuyuki Yamataka
Journal:  Pediatr Surg Int       Date:  2017-10-05       Impact factor: 1.827

2.  Clinical outcomes and risk factors for postoperative complications in children with Hirschsprung's disease.

Authors:  Tingting Gao; Weijue Xu; Qingfeng Sheng; Ting Xu; Wei Wu; Zhibao Lv
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

3.  One-stage transanal endorectal pull-through for Hirschsprung disease: experience with 229 neonates.

Authors:  Yanan Zhang; Zhaozhou Liu; Shuangshuang Li; Shen Yang; Jiawei Zhao; Ting Yang; Siqi Li; Yongwei Chen; Weihong Guo; Dawei Hou; Yingzi Li; Jinshi Huang
Journal:  Pediatr Surg Int       Date:  2022-08-28       Impact factor: 2.003

Review 4.  Management and outcomes for long-segment Hirschsprung disease: A systematic review from the APSA Outcomes and Evidence Based Practice Committee.

Authors:  Akemi L Kawaguchi; Yigit S Guner; Stig Sømme; Alexandria C Quesenberry; L Grier Arthur; Juan E Sola; Cynthia D Downard; Rebecca M Rentea; Patricia A Valusek; Caitlin A Smith; Mark B Slidell; Robert L Ricca; Roshni Dasgupta; Elizabeth Renaud; Doug Miniati; Jarod McAteer; Alana L Beres; Julia Grabowski; Shawn D St Peter; Ankush Gosain
Journal:  J Pediatr Surg       Date:  2021-03-28       Impact factor: 2.549

Review 5.  ERNICA guidelines for the management of rectosigmoid Hirschsprung's disease.

Authors:  Kristiina Kyrklund; Cornelius E J Sloots; Ivo de Blaauw; Kristin Bjørnland; Udo Rolle; Duccio Cavalieri; Paola Francalanci; Fabio Fusaro; Annette Lemli; Nicole Schwarzer; Francesco Fascetti-Leon; Nikhil Thapar; Lars Søndergaard Johansen; Dominique Berrebi; Jean-Pierre Hugot; Célia Crétolle; Alice S Brooks; Robert M Hofstra; Tomas Wester; Mikko P Pakarinen
Journal:  Orphanet J Rare Dis       Date:  2020-06-25       Impact factor: 4.123

6.  Atypical onset of total colonic Hirschsprung disease in a small female infant: A case report.

Authors:  Cristina Oana Mărginean; Lorena Elena Meliţ; Horea Gozar; Emoke Horvath; Cristian Dan Mărginean
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

7.  Long-term functional outcomes and quality of life in patients with Hirschsprung's disease.

Authors:  R J Meinds; A F W van der Steeg; C E J Sloots; M J Witvliet; I de Blaauw; W G van Gemert; M Trzpis; P M A Broens
Journal:  Br J Surg       Date:  2019-01-17       Impact factor: 6.939

8.  Classification of short-term complications after transanal endorectal pullthrough for Hirschsprung's disease using the Clavien-Dindo-grading system.

Authors:  Nils Hoff; Tomas Wester; Anna Löf Granström
Journal:  Pediatr Surg Int       Date:  2019-08-14       Impact factor: 1.827

9.  Long-term outcomes and quality of life of patients with Hirschsprung disease: a systematic review and meta-analysis.

Authors:  Ying Dai; Yongfang Deng; Yan Lin; Runxian Ouyang; Le Li
Journal:  BMC Gastroenterol       Date:  2020-03-12       Impact factor: 3.067

10.  Optimal timing for Soave primary pull-through in short-segment Hirschsprung disease: A meta-analysis.

Authors:  Maggie L Westfal; Ongoly Okiemy; Patrick Ho Yu Chung; Jiexiong Feng; Changgui Lu; Go Miyano; Paul Kwong Hang Tam; Weibing Tang; Kenneth Kak Yuen Wong; Atsuyuki Yamataka; Richard A Guyer; Daniel P Doody; Allan M Goldstein
Journal:  J Pediatr Surg       Date:  2021-07-21       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.